Certara

EQT VII acquires Certara for $850M

Wednesday, July 12, 2017

The EQT VII fund has agreed to acquire Certara, a provider of technology-driven decision support solutions for drug development, for an enterprise value of $850 million. The company is being acquired from Arsenal Capital Partners. As part of the transaction, Arsenal Capital Partners will retain a minority ownership stake in Certara, with the Company’s current management team, led by Edmundo Muniz, M.D., Ph.D., continuing to lead the organization, building on a multi-year track record of both organic growth and strategic acquisitions.

[Read More]

Certara launches CODEx

Tuesday, June 6, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, launched its Clinical Outcomes Database Explorer (CODEx). An intuitive, web-based platform, CODEx enables drug development teams to easily visualize, explore, analyze and communicate content from Certara’s Clinical Trial Outcomes Databases and assess a given compound’s probability of success against competitor drugs.

[Read More]

Certara launches Simcyp Access to expand simulator availability

Thursday, March 9, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced the launch of Simcyp Access. This new cloud-based licensing approach provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects. 

[Read More]

Certara Strategic Consulting awarded GLP compliant toxicokinetic test site certification

Wednesday, February 22, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that the Standards Council of Canada (SCC) has awarded Good Laboratory Practices (GLP) certification to its Certara Strategic Consulting (CSC) Montreal facility. CSC Montreal has passed the requisite inspection and study audits and is now recognized as a GLP compliant Toxicokinetic Test Site by SCC.

[Read More]

Certara Vice President Piet van der Graaf appointed F1000Prime faculty member

Thursday, February 16, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that Professor Piet van der Graaf, PharmD, Ph.D., its vice president of quantitative systems pharmacology, has been appointed an F1000Prime faculty member. In this new role, Professor van der Graaf will contribute article reviews and recommendations to the Systems & Network Biology Section of the Bioinformatics, Biomedical Informatics & Computational Biology Faculty. He will be responsible for summarizing each article, explaining its value, and adding a rating score.

[Read More]

Certara releases new version of informatics platform D360

Tuesday, January 31, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has released D360 version 9.0 along with D360 Express, its data informatics platform for discovery scientists. D360 is a self-service data access, integration and visualization solution used to query multiple cheminformatics and bioinformatics data sources and make informed go/no-go and next step research decisions. It is used by more than 5,000 scientists worldwide at both large pharma and specialty research organizations.

[Read More]